BC Extra | Sep 20, 2019
Company News

Approval of Novo’s Rybelsus gives diabetes patients first oral option in GLP-1R class

FDA’s approval Friday of Rybelsus, the first oral GLP-1R agonist for diabetes, brings across the finish line a critical drug for Novo Nordisk’s growth strategy after the company prioritized best-in-class R&D three years ago. After...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Extra | Jun 22, 2016
Company News

Management tracks

Endocyte Inc. (NASDAQ:ECYT) said Ron Ellis resigned as president and CEO. The cancer company promoted CFO and COO Mike Sherman to succeed Ellis. Sherman will remain CFO. Bristol-Myers Squibb Co. (NYSE:BMY) promoted Murdo Gordon to...
BC Week In Review | Nov 16, 2015
Company News

Emisphere, Novo Nordisk deal

Emisphere granted Novo Nordisk worldwide rights to develop and commercialize oral formulations of four classes of Novo’s products, including those for diabetes and obesity, using Emisphere’s oral Eligen technology. Emisphere granted Novo exclusive rights to...
BC Week In Review | Feb 23, 2015
Clinical News

Oral semaglutide: Phase II data

A double-blind, international Phase II trial in about 600 Type II diabetics showed that all 5 doses of once-daily oral semaglutide met the primary endpoint of reducing HbA1c from baseline to week 26 vs. placebo....
BC Week In Review | Sep 1, 2014
Financial News

Emisphere completes debt financing

Emisphere Technologies Inc. (OTCBB:EMIS), Cedar Knolls, N.J.   Business: Drug delivery   Date completed: 2014-08-20   Type: Debt financing   Raised: $5 million   Investor: MHR Fund Management LLC   Note: Emisphere drew down $5...
BC Innovations | Dec 19, 2013
Cover Story

Oral nanoparticles

Researchers from Brigham and Women's Hospital and the Massachusetts Institute of Technology have developed targeted nanoparticles that could enable the oral delivery of biologics such as insulin. 1 The clinical translation of the approach will...
BC Week In Review | Aug 19, 2013
Clinical News

Oral semaglutide: Phase I data

Novo Nordisk disclosed in its 2Q13 earnings that data from 5 Phase I trials in 400 healthy volunteers and 10 Type II diabetics showed that oral semaglutide was well tolerated. In a 10-week Phase I...
BC Week In Review | May 6, 2013
Company News

Emisphere, Novo Nordisk deal

Emisphere and Novo Nordisk amended a 2008 deal granting Novo Nordisk an exclusive license to use Emisphere's Eligen drug delivery technology to develop and commercialize oral formulations of Novo Nordisk's glucagon-like peptide-1 (GLP-1) receptor agonists...
Items per page:
1 - 10 of 306
BC Extra | Sep 20, 2019
Company News

Approval of Novo’s Rybelsus gives diabetes patients first oral option in GLP-1R class

FDA’s approval Friday of Rybelsus, the first oral GLP-1R agonist for diabetes, brings across the finish line a critical drug for Novo Nordisk’s growth strategy after the company prioritized best-in-class R&D three years ago. After...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Extra | Jun 22, 2016
Company News

Management tracks

Endocyte Inc. (NASDAQ:ECYT) said Ron Ellis resigned as president and CEO. The cancer company promoted CFO and COO Mike Sherman to succeed Ellis. Sherman will remain CFO. Bristol-Myers Squibb Co. (NYSE:BMY) promoted Murdo Gordon to...
BC Week In Review | Nov 16, 2015
Company News

Emisphere, Novo Nordisk deal

Emisphere granted Novo Nordisk worldwide rights to develop and commercialize oral formulations of four classes of Novo’s products, including those for diabetes and obesity, using Emisphere’s oral Eligen technology. Emisphere granted Novo exclusive rights to...
BC Week In Review | Feb 23, 2015
Clinical News

Oral semaglutide: Phase II data

A double-blind, international Phase II trial in about 600 Type II diabetics showed that all 5 doses of once-daily oral semaglutide met the primary endpoint of reducing HbA1c from baseline to week 26 vs. placebo....
BC Week In Review | Sep 1, 2014
Financial News

Emisphere completes debt financing

Emisphere Technologies Inc. (OTCBB:EMIS), Cedar Knolls, N.J.   Business: Drug delivery   Date completed: 2014-08-20   Type: Debt financing   Raised: $5 million   Investor: MHR Fund Management LLC   Note: Emisphere drew down $5...
BC Innovations | Dec 19, 2013
Cover Story

Oral nanoparticles

Researchers from Brigham and Women's Hospital and the Massachusetts Institute of Technology have developed targeted nanoparticles that could enable the oral delivery of biologics such as insulin. 1 The clinical translation of the approach will...
BC Week In Review | Aug 19, 2013
Clinical News

Oral semaglutide: Phase I data

Novo Nordisk disclosed in its 2Q13 earnings that data from 5 Phase I trials in 400 healthy volunteers and 10 Type II diabetics showed that oral semaglutide was well tolerated. In a 10-week Phase I...
BC Week In Review | May 6, 2013
Company News

Emisphere, Novo Nordisk deal

Emisphere and Novo Nordisk amended a 2008 deal granting Novo Nordisk an exclusive license to use Emisphere's Eligen drug delivery technology to develop and commercialize oral formulations of Novo Nordisk's glucagon-like peptide-1 (GLP-1) receptor agonists...
Items per page:
1 - 10 of 306